DrugPatentWatch Database Preview
DEFINITY Drug Profile
When do Definity patents expire, and when can generic versions of Definity launch?
Definity is a drug marketed by Lantheus Medcl and is included in one NDA. There are four patents protecting this drug.
This drug has fifty-four patent family members in thirty-two countries.
The generic ingredient in DEFINITY is perflutren. One supplier is listed for this compound. Additional details are available on the perflutren profile page.
Summary for DEFINITY
| International Patents: | 54 |
| US Patents: | 4 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 33 |
| Clinical Trials: | 49 |
| Patent Applications: | 1,497 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for DEFINITY |
| DailyMed Link: | DEFINITY at DailyMed |
Generic Entry Opportunity Date for DEFINITY
Generic Entry Date for DEFINITY*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
INJECTABLE;INTRAVENOUS |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for DEFINITY
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| National Institute on Aging (NIA) | N/A |
| Elisa Konofagou | N/A |
| UNC Lineberger Comprehensive Cancer Center | Phase 3 |
Pharmacology for DEFINITY
| Drug Class | Contrast Agent for Ultrasound Imaging |
| Mechanism of Action | Ultrasound Contrast Activity |
Synonyms for DEFINITY
| 1,1,1,2,2,3,3,3-Octafluoropropane |
| 1,1,1,2,2,3,3,3-octakis(fluoranyl)propane |
| 218599-63-4 |
| 300408-51-9 |
| 76-19-7 |
| A838638 |
| AC1L1MIR |
| AC1Q4IBX |
| AKOS006228213 |
| AN-23892 |
| AN-37829 |
| C-50894 |
| C3F8 |
| C3F8-gas |
| CHEBI:31980 |
| CHEMBL1663 |
| CK0N3WH0SR |
| CTK5E2580 |
| D01738 |
| DB-056033 |
| DB00556 |
| Definity (TN) |
| DMP 115 |
| DMP-115 |
| DTXSID9052503 |
| EC 200-941-9 |
| EINECS 200-941-9 |
| FC 218 |
| FC 218 (refrigerant) |
| FCH918400 |
| Flutec PP30 |
| Freon 218 |
| FS-069 |
| FS069 |
| FT-0621948 |
| FT-0631321 |
| Genetron 218 |
| HFC 218 |
| HSDB 8074 |
| I14-14876 |
| KB-59511 |
| liposome-encapsulated perfluoropane microsphere |
| LS-120891 |
| MRX 115 |
| MRX-115 |
| OCTAFLUOROPROPANE |
| octafluoropropane-lipid microsphere |
| Octafluoropropaneor Refrigerant gas R 218 |
| Octafluoropropaneor Refrigerant gas R 218 [UN2424] [Nonflammable gas] |
| Octafluoropropaneor Refrigerant gas R 218 [UN2424] [Nonflammable gas] |
| Octafluorpropan |
| Oktafluorpropan |
| Optison |
| Optison (Salt/Mix) |
| Perfluoropropane |
| Perfluoropropane (PFC-218) 99.9% |
| Perfluoropropane 99+% |
| Perfluoropropaneminimum |
| Perflutren |
| Perflutren (JAN/USAN/INN) |
| Perflutren [USAN:INN:BAN] |
| Perflutren [USAN] |
| Perflutren and Human Albumin |
| Perflutren Lipid Microsphere |
| Perflutren lipid microspheres |
| Perflutren Protein-Type A Microspheres injection |
| Perflutren-lipid microsphere |
| PFC 218 |
| Propane, 1,1,1,2,2,3,3,3-octafluoro- |
| Propane, octafluoro- |
| Propane,1,1,1,2,2,3,3,3-octafluoro- |
| QYSGYZVSCZSLHT-UHFFFAOYSA-N |
| R 218 |
| RC 218, PFC 218 |
| SBB090673 |
| UN 2424 |
| UN2424 |
| UNII-CK0N3WH0SR |
| YM454 |
| ZINC8214651 |
| ZX-AP010865 |
US Patents and Regulatory Information for DEFINITY
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lantheus Medcl | DEFINITY | perflutren | INJECTABLE;INTRAVENOUS | 021064-001 | Jul 31, 2001 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Lantheus Medcl | DEFINITY | perflutren | INJECTABLE;INTRAVENOUS | 021064-001 | Jul 31, 2001 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
| Lantheus Medcl | DEFINITY | perflutren | INJECTABLE;INTRAVENOUS | 021064-001 | Jul 31, 2001 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Lantheus Medcl | DEFINITY | perflutren | INJECTABLE;INTRAVENOUS | 021064-001 | Jul 31, 2001 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for DEFINITY
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Lantheus Medcl | DEFINITY | perflutren | INJECTABLE;INTRAVENOUS | 021064-001 | Jul 31, 2001 | Start Trial | Start Trial |
| Lantheus Medcl | DEFINITY | perflutren | INJECTABLE;INTRAVENOUS | 021064-001 | Jul 31, 2001 | Start Trial | Start Trial |
| Lantheus Medcl | DEFINITY | perflutren | INJECTABLE;INTRAVENOUS | 021064-001 | Jul 31, 2001 | Start Trial | Start Trial |
| Lantheus Medcl | DEFINITY | perflutren | INJECTABLE;INTRAVENOUS | 021064-001 | Jul 31, 2001 | Start Trial | Start Trial |
| Lantheus Medcl | DEFINITY | perflutren | INJECTABLE;INTRAVENOUS | 021064-001 | Jul 31, 2001 | Start Trial | Start Trial |
| Lantheus Medcl | DEFINITY | perflutren | INJECTABLE;INTRAVENOUS | 021064-001 | Jul 31, 2001 | Start Trial | Start Trial |
| Lantheus Medcl | DEFINITY | perflutren | INJECTABLE;INTRAVENOUS | 021064-001 | Jul 31, 2001 | Start Trial | Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for DEFINITY
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Eurasian Patent Organization | 002978 | Start Trial |
| Canada | 3025580 | Start Trial |
| Japan | 2019521130 | Start Trial |
| Australia | 2115599 | Start Trial |
| Slovakia | 10312000 | Start Trial |
| Portugal | 1419789 | Start Trial |
| Austria | 447976 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for DEFINITY
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0712293 | C300267 | Netherlands | Start Trial | PRODUCT NAME: PERFLUTREN BEVATTENDE LIPIDE-MICROBOLLEN; REGISTRATION NO/DATE: EU/1/06/361/001 20060920 |
| 0712293 | 0790017-8 | Sweden | Start Trial | PRODUCT NAME: LIPIDMIKROSFAERER INNEHALLANDE PERFLUTREN; REG. NO/DATE: EU/1/06/361/001 20060920 |
| 0712293 | SPC/GB07/031 | United Kingdom | Start Trial | PRODUCT NAME: PERFLUTREN-CONTAINING LIPID MICROSPHERES; REGISTERED: UK EU/1/06/361/001 20060920 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
